PExA (PEXA) Q1 2026 earnings summary

Executive summary

• Achieved net sales of 1,105,759 SEK in Q1 2026, up from 0 SEK in Q1 2025, surpassing full-year 2025 sales already in the first quarter.

• Result after financial items improved to -952,641 SEK from -2,248,575 SEK year-over-year.

• Strategic repositioning from research instrument provider to a broader technology platform for biomarker discovery, PK/PD, and diagnostics.

• Significant media and scientific exposure, including new patents and international research collaborations.

Financial highlights

• Net sales: 1,105,759 SEK (Q1 2026) vs. 0 SEK (Q1 2025).

• Result after financial items: -952,641 SEK (Q1 2026) vs. -2,248,575 SEK (Q1 2025).

• Cash and bank: 3,817,723 SEK at period end (vs. 3,867,797 SEK prior year).

• Equity ratio: 76.5% (Q1 2026) vs. 77.6% (Q1 2025).

• Cash flow from operations: -1,492,759 SEK (Q1 2026) vs. -1,725,636 SEK (Q1 2025).

Outlook and guidance

• Board assesses current funds are insufficient for the next 12 months; evaluating options for additional capital.

• Continued focus on expanding technology platform and building long-term value through customer relationships, data, and patents.